Treatment with the glucagon receptor antagonist <scp>LY2409021</scp> increases ambulatory blood pressure in patients with type 2 diabetes

Abstract

Statistically significant increases in BP, MAP and serum lipid levels were observed with LY2409021 treatment at a dose that lowered HbA1c and glucose levels. These effects may limit the clinical utility of LY2409021 as a chronic treatment for type 2 diabetes.